BCMA Binding Domain Compositions for Hematological Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel therapeutics that target B-cell maturation antigen (BCMA) for the treatment of hematological diseases such as multiple myeloma, as existing treatments are inadequate.
Innovation Solution
Development of novel BCMA antigen binding domain compositions and antibodies that include specific variable light and heavy domains, which are used to create heterodimeric and bispecific antibodies capable of binding to BCMA, thereby providing a therapeutic option for BCMA-associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibody-based therapeutics are used to treat hematological diseases, then treatment options are available, but the treatments are inadequate for BCMA-associated diseases
Solution Approach 1:
The patent develops novel antibody compositions with specific variable light and heavy domain configurations (different CDR sequences) to create heterodimeric and bispecific antibodies with optimized binding characteristics to BCMA, thereby improving treatment efficacy for BCMA-associated diseases
Solution Approach 2:
The patent creates composite antibody structures by combining different variable domains (VH and VL) to form heterodimeric antibodies, and further combines multiple antigen binding domains to create bisspecific antibodies that can target multiple antigens simultaneously, enhancing both efficacy and therapeutic coverage
2Adaptability or versatility
If novel BCMA antigen binding domain compositions are developed, then therapeutic options are enhanced, but the complexity of antibody structure increases
Solution Approach 1:
The patent divides the antibody into distinct functional modules: variable domains (VH and VL) with specific CDR regions for antigen binding, and constant domains for effector functions. This segmentation allows systematic design of heterodimeric and bisspecific configurations while maintaining structural organization
Solution Approach 2:
The patent designs antibody frameworks with universal constant domains that can be combined with different variable domain configurations to create multiple therapeutic variants targeting BCMA, allowing one structural platform to serve multiple therapeutic purposes
Data Source
AI summary
Provided herein are novel BCMA binding domain compositions and anti-BCMA antibodies that include such BCMA binding domains.